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primary liver malignancy and accounts for 80% of all liver
tumours [1]. Worldwide, HCC is the fifth most commonly
diagnosed cancer, and ranks as the fourth leading cause of
cancer-related deaths [2,3]. Furthermore, the incidence rate
of HCC has steadily increased over the past 3 decades within
Canada and is projected to continue to increase over the next
10 years [2]. There are several well-established risk factors
for the development of HCC, the most recognized being
chronic hepatitis B and hepatitis C infection [3]. Hepatitis B
carriers have been reported to have a relative risk of HCC,
which is 100 times greater than the background population,
and this figure is likely to be greater if there is established
cirrhosis [4]. In fact, liver cirrhosis of any etiology,* Address for correspondence: David Liu, MD, FRCPC, CAQ(IR),
ABR(D), 855 W 12th Ave, Vancouver General Hospital, JP Pavillion Ground
Floor, Department of Radiology, Vancouver, British Columbia V5Z 1M9,
Canada.
E-mail address: Dave.Liu@vch.ca (D. Liu).
0846-5371/$ - see front matter Crown Copyright  2012 Published by Elsevier
doi:10.1016/j.carj.2011.09.004especially genetic hemochromatosis and alcohol-related
cirrhosis, has been implicated in the development of HCC
[3]. The incidence of HCC is higher among men, particularly
in those who are from southeast Asia and Sub-Saharan
Africa compared with women [3]. In North America, viral
hepatitis, chronic liver disease that leads to cirrhosis, and,
therefore, HCC are diseases that are predominant in large
urban centres.
In addition to the assessment of risk factors and clinical
presentation, the diagnosis of HCC typically relies on the use
of imaging. However, due to the complex imaging presen-
tation of cirrhosis, the diagnosis of HCC on the background
of extensive fibrosis, regenerative nodule formation, and
morphologic changes to the liver presents a challenge. As
a result, clinicians may feel that histologic evaluation is
necessary to make a definitive diagnosis. However, biopsy of
a suspected HCC is not without risk. First, a biopsy is an
invasive procedure that can cause pain and discomfort, and
may require sedation to perform satisfactorily [5]. There alsoInc on behalf of Canadian Association of Radiologists. All rights reserved.
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causing vascular injury, which can result in bleeding or the
creation of an arteriovenous fistula.
Postprocedural hemorrhage is the most common serious
complication of percutaneous liver biopsy, with rates that
range from 0.3%-1.7%, and requires hospitalization [5e9].
Another significant concern is the potential for tumour
seeding via local rupture of the tumour as a result of the
biopsy itself, as well as tumour tract seeding along the path
of the biopsy device or spillage of tumour into the perito-
neum [3]. The rate of needle tract seeding during a percuta-
neous fine-needle biopsy of HCC has been reported to be in
the range of 2%-3% (Figure 1) [3,10,11].
In July of 2010, the Practice Guidelines Committee of the
American Association for Study of Liver Disease (AASLD)
published an updated version of their guidelines that outlines
the indications and recommendations for when biopsy is not
indicated in patients with suspected HCC. The intent of this
pictorial essay is to review these guidelines as well as to
provide examples of the imaging characteristics associated
with HCC.
Pathophysiology
The development of HCC in the cirrhotic liver is described
either as de novo hepatocarcinogenesis or as a stepwise
progression [12]. In the latter case, the development of
a benign regenerative nodule may be the first step in the
carcinogenesis of the liver [1]. This lesion may then further
develop through phases from a low-grade dysplastic nodule to
a high-grade dysplastic nodule to early HCC, in a multistepFigure 1. After needle biopsy of pathologically proven hepatocellular carcinom
computed tomographic images on the portal venous phase, demonstrating soft-ti
(C), and subcutaneous tissues (D) after needle biopsy of a liver mass, which was p
needle tumour tract seeding, which resulted in a significantly different surgicalfashion [1]. A malignant transformation evolves within these
lesions, there is a gradual reduction of normal hepatic arterial
and portal venous supply, in conjunction with an increase in
abnormal arterial supply [12].
A regenerative nodule represents a hepatocellular nodule
that maintains its portal tracts and, thus, continues to receive
its blood supply largely from the portal vein, with minimal
contribution from the hepatic artery. In contrast, a dysplastic
nodule demonstrates cellular dysplasia but does not meet
histologic criteria for malignancy and is considered to be
a premalignant lesion [12]. As the grade of malignancy
within the nodule evolves, preferential neovascularization via
the arterial supply increases secondary to tumour angiogen-
esis [12]. As a result, HCCs are typically supplied by
abnormal neovascular arteries and, thus, demonstrate arterial
hypervascularity [1]. Early HCCs have a variable degree of
arterial and portal venous supply, whereas high-grade or
poorly differentiated HCCs contain a large number of
abnormal arteries (almost exclusively from the hepatic arte-
rial supply) and a near absence of normal portal tracts (and,
therefore, portal venous perfusion) [1]. This very important
characteristic of HCC is one way that these lesions can be
differentiated from regenerative nodules and dysplastic
nodules on imaging.
The distinctive blood supply of HCCs can be displayed by
using contrast enhanced imaging (ultrasound [US], computed
tomography [CT], or magnetic resonance imaging [MRI]) to
demonstrate a characteristic phenomenon known as
‘‘contrast washout.’’ This requires a multiphasic contrast-
enhanced study, in particular, looking at the arterial and
venous phases that allows for assessment of the vascularitya (HCC), resulting in tumour tract seeding. Contrast-enhanced transaxial
ssue changes within the right pleura (A), right hemithorax (B), musculature
roven to be HCC on pathology. These changes, indicated by arrows, represent
approach with wider resection margins.
Figure 2. At-risk population in whom screening for hepatocellular carcinoma (HCC) is recommended.
Figure 3. Algorithm outlining the investigation of liver nodules detected during screening. CT ¼ computed tomography; HCC ¼ hepatocellular carcinoma;
MDCT ¼ multidetector CT; MRI ¼ magnetic resonance imaging; US ¼ ultrasound.
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enhances more intensely compared with the surrounding
liver parenchyma, because the process of vascular recruit-
ment and angioneogenesis is almost exclusively drawn from
the hepatic arterial supply, whereas the remainder of the liver
is perfused by noncontrast enhanced portal venous blood
[13]. Conversely, in the portal venous phase, contrast has
‘‘washed out’’ of the HCC lesion, whereas the surrounding
liver parenchyma still receives contrast-enhanced blood via
the portal system. Therefore, during the portal venous phase,
HCCs enhance less intensely compared with the remainder
of the liver. The finding of arterial contrast enhancement
followed by portal venous washout is considered to be highly
specific for the diagnosis of HCC [13].
Another characteristic feature of HCC is its tendency to
invade and grow into the portal and hepatic veins and bile
ducts, which results in the classic characteristics of macro-
scopic portal, hepatic, venous, and biliary invasion as
demonstrated on imaging. This is in contradistinction to
secondary liver malignancies and is a finding that can help
distinguish HCC from liver metastases [1].
Screening
Screening is recommended for individuals who are
considered at high risk for developing HCC. The at-riskFigure 4. Characteristic ultrasonographic (US) findings of hepatocellular carcino
US image, demonstrating a circular hypoechoic mass within the liver without post
A 66-year-old man with hepatitis C. Transverse transabdominal US image, dem
deposit within it (arrow). (C) A 70-year-old woman with hepatitis B. A furthe
heterogenous, predominantly hyperechoic mass (arrow) within the liver, with in
(>3 cm) to have a propensity towards internal necrosis. The accompanying contra
the internal necrotic characteristics of the HCC (arrow).populations for whom the efficacy of screening has been
demonstrated are outlined in Figure 2 [13]. Screening tests
for HCC fall under 1 of 2 categories, notably serologic and
radiologic testing. The serologic marker that has best been
studied in this regard is alpha-fetoprotein (AFP). Currently,
an AFP cutoff value of 20 ng/mL is considered to provide
the most optimal balance between sensitivity and specificity
of this marker for the diagnosis of HCC [13]. However, this
confers a sensitivity of only 60% for the detection of HCC,
which means that 40% of cases would be missed on
screening by using this cutoff value. Other cutoff values
would have the inherent disadvantage of exceedingly high
false-positive or false-negative results. Furthermore, AFP
has been shown to be elevated in cases of intrahepatic
cholangiocarcinoma, in some cases of colon cancer metas-
tases, and it is well recognized that an AFP can be elevated
on the basis of chronic viral hepatitis in the absence of
HCC [14,15]. Therefore, AFP serology has fallen out of
favor as a screening tool for HCC, with the most widely
accepted tool for HCC surveillance in the at-risk population
being US [13].
Approach to Diagnosis
According to the AASLD 2010 guidelines (updated 2010
AASLD Criteria), HCC can be diagnosed radiologicallyma (HCC). (A) A 51-year-old man with hepatitis C. Sagittal transabdominal
erior enhancement consistent with the characteristic US findings of HCC. (B)
onstrating a predominantly hypoechoic HCC with focal echogenic nodular
r example of focal HCC, demonstrating increased echogenicity. (D) Large
ternal hypoechoic architecture, demonstrating the tendency for larger HCCs
st-enhanced transaxial computed tomography of the same patient, illustrating
Figure 5. Hepatocellular carcinoma (HCC) on Dopppler imaging in
a 70-year-old woman with hepatitis C. (A) Transverse transabdominal
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diagnostic features are present on imaging. The major
difference between the previous (2005) and current AASLD
guidelines involves the exclusion of the 1-2ecm size cate-
gory and the corresponding use of 2 contrast-enhanced
diagnostic tests to confirm HCC. Results of several studies
have provided external validation that the typical appear-
ances of arterial hypervascularity and venous washout within
this subgroup are so highly specific that only a single study is
necessary if these appearances are present [13]. Furthermore,
contrast-enhanced US has been omitted from the updated
guidelines in the diagnosis of HCC. This decision was based
on concerns regarding reports of false-positive results for
HCC in patients with biopsy proven intrahepatic chol-
angiocarcinoma [13].
The most current algorithm for the investigation of
nodules found on screening US for at-risk populations is
summarized in Figure 3 [13]. Lesions that measure <1 cm
are generally considered to have a low probability of being
HCC [3]. However, given the potential for carcinogenesis
over time, the guidelines propose that a close follow-up
regimen be initiated. This consists of US follow-up at
6-monthly intervals in high-risk populations, the finding of
a new nodule or an enlarging mass, even if previously
considered benign, requires further evaluation [13]. Lesions
that are >1 cm should be further investigated with either
a 4-phase multidetector CT, or dynamic contrast-enhanced
MRI. Of note, the AASLD criteria do not designate
which study is to be used initially and which to use for
follow-up. If there is arterial hypervascularity and portal
venous or delayed-phase contrast washout, as previously
described, the diagnosis of HCC can be made. If the find-
ings are not characteristic of HCC based on the afore-
mentioned criteria, 1 of 2 approaches may be followed. An
alternate contrast study can be performed, which, if
consistent with the typical appearance of HCC, confirms the
diagnosis. Alternatively, the clinician may choose to biopsy
the lesion at this point. If the results of the second imaging
study are not consistent with HCC, then a biopsy should be
performed.
If a lesion is biopsied based on the AASLD recommen-
dations, but histopathologic analysis is negative for HCC,
then the lesion should be followed up radiologically at
intervals of 3-6 months until the lesion disappears, enlarges,
or displays the diagnostic appearance of HCC [13]. There
currently are no data to establish the best follow-up policy,
but the AASLD guidelines recommend repeated biopsy or
follow-up CT or MRI to detect further growth. If the lesion
enlarges but remains atypical for HCC, then repeated biopsy
is recommended [13].ultrasound (US), showing a well-circumscribed rounded mass (arrow) of
mixed echogenicity bulging the surface contour of the left lobe of the liver.
(B, C) Colour Doppler US, demonstrating interval vascularity within the
tumour as well as a peritumoural hypervascular ring, giving the character-
istic ‘‘basket pattern.’’ This figure is available in colour online at http://www.
carjonline.org/.
Figure 6. Additional findings on ultrasound (US) consistent with hepatocellular carcinoma (HCC). (A, B) Tumoural thrombus is located within the main portal
vein (arrow). Colour Doppler US, demonstrating flow within the thrombus, indicating tumoural thrombus rather than bland thrombus. (C) Echogenic material is
identified within the common bile duct (arrowhead), consistent with tumoural invasion. (D) Transverse transabdominal US, showing intrahepatic biliary duct
dilatation. (E) The contrast-enhanced transaxial computed tomography, demonstrating a hepatic mass and exhibiting mass effect, and compressing on the
adjacent biliary ducts and resulting in intrahepatic biliary duct dilatation. This figure is available in colour online at http://www.carjonline.org/.
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US is a primary technique for imaging the liver, biliary
tree, and gallbladder. Furthermore, US has a reported
sensitivity and specificity of 60%-80% and >90%, respec-
tively, for the detection of HCC [13]. The appearance of
HCC is variable, depending on lesion composition and size.
Most small HCCs (<3 cm) generally appear as slightly
hypoechoic nodules, without posterior enhancement, within
a background of a heterogenous-appearing cirrhotic liver
(Figure 4A) [16,17]. HCCs also can appear hyperechoic dueto fatty deposition, sinusoidal dilatation, or fibrosis, which
can make them difficult to distinguish from a cavernous
hemangioma or focal fatty deposition (Figure 4, B and C)
[16]. Lesions >3 cm have a tendency towards internal
necrosis and show a more heterogenous pattern of echoge-
nicity (Figure 4D) [17].
Doppler US is useful in demonstrating the presence of
arterial hypervascularity within the tumour as well as the
typical morphology of intra- and peritumoural vessels,
referred to as the ‘‘basket pattern’’ (Figure 5) [1]. Power
Doppler US, which registers the amplitude of Doppler shifts
Figure 7. Contrast enhanced ultrasound of a 59-year-old man with hepatocellular carcinoma (HCC). (A) Sagittal contrast-enhanced of a liver mass,
demonstrating enhancement during the arterial phase of the study (arrows). (B) This mass exhibits the characteristic washout on the portal venous phases,
consistent with HCC (arrows).
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Doppler US for the detection of small vessels and flow within
tumours [16,17]. Other findings on US consistent with
a diagnosis of HCC include portal or hepatic venous throm-
bosis, displacement or compression of the intrahepatic blood
vessels, or segmental bile duct obstruction (Figure 6) [17].
However, delineation of these findings is often challenging.
It also is possible to demonstrate arterial enhancement and
portal venous washout of HCC with the aid of US contrast
agents (Figure 7). These agents are typically solutions of
coated microbubbles that act as acoustic reflectors andappear echogenic on US imaging [16e18]. In the setting of
the AASLD guidelines, there is no current role for contrast-
enhanced US due to the unavailability in the United States
[18]. Given the impending regulatory approval of several
new agents, contrast-enhanced US will likely be incorporated
into subsequent iterations and revisions.
CT
A multiphasic multidetector CT can systematically eval-
uate the liver parenchyma, hepatic arteries, hepatic veins,
Figure 8. Characteristic computed tomographic (CT) findings of hepato-
cellular carcinoma (HCC). (A) Transaxial contrast-enhanced CT on the
arterial phase, illustrating a hyperenhancing liver mass (arrows). (B) The
portal venous phase highlights the washout of the mass to hypoattenuating in
comparison with the surrounding liver parenchyma, characteristic for an
HCC.
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portal venous, and delayed or equilibrium phases. In the
nonenhanced phase, siderotic regenerative nodules show
higher attenuation than the surrounding liver parenchyma,
and, thus, this study phase is useful to ensure that these
nodules are not mistaken for enhancing nodules in the arte-
rial phase [17]. Small HCCs are well defined with smooth
encapsulated margins, however, large diffuse infiltrative
lesions with poorly defined margins (especially those with
frank venous invasion) are also described [17].
In the arterial phase, the typical HCC shows intense
enhancement as a result of hypervascularity secondary to
tumour neoangiogenesis [16,17]. The fibrous capsule has no
marked enhancement during this phase. Tumour thrombosis
may also be visualized during this phase and can be distin-
guished from benign thrombosis, which does not demon-
strate contrast enhancement [17]. During the portal venous
phase, HCC shows contrast washout and, therefore, appears
as a hypoattenuating lesion relative to the surrounding liver
parenchyma (Figure 8) [16,17]. At the same time, the fibrous
capsule shows gradual enhancement [17].
In the delayed phase, HCC continues to appear as
a hypoenhancing lesion within the liver parenchyma.
Conversely, the fibrous capsule typically retains contrast
medium and, therefore, appears hyperdense [17]. According
to some researchers, small HCCs (<3 cm) are most easily
visualized during the delayed phase scan and appear hypo-
dense compared with liver parenchyma [19,20]. The use of
multidetector CT allows for a comprehensive assessment of
any metastatic spread to periportal or retroperitoneal lymph
nodes (Figure 9) or to the peritoneal cavity [16].
MRI
Multiphasic gadolinium-enhanced T1-weighted MRI of
HCC demonstrates findings that are similar to those found on
multiphasic contrast-enhanced CT, namely arterial phase
hypervascularity and portal venous or delayed phase contrast
washout (Figure 10) [1,16,17]. HCC displays variable signal
intensity onT1-weighted scans.Well-differentiatedHCCsmay
appear as high-intensity nodules compared with the
surrounding liver parenchyma, in part, due to the fatty content
of these tumours aswell as the presence of copper, glycogen, or
zinc in the surrounding parenchyma (Figure 11 and Figure 12,
E and F) [1,12,16], which is in contrast to the more poorly
differentiated tumours, which commonly have lower signal
intensity on T1-weighted imaging [1,16].
HCC typically appears as a higher signal intensity nodule
on T2-weighted scans [12,16,17]. In fact, a hyperintense
nodule seen within a cirrhotic liver on T2-weighted imaging
is considered to be highly suggestive of a malignancy [1]. The
fibrous capsule appears as a low signal rim on both T1- and
T2-weighted images [1].
Regenerative nodules are typically isointense on both
T1- and T2-weighted images and do not enhance during the
arterial phase on a contrast-enhanced study (Figure 12, A-D)
[17,21]. Less commonly, they may appear hyperintense onT1-weighted imaging due to the presence of lipid, protein, or,
possibly, copper [12]. Furthermore, siderotic regenerative
nodules may appear hypointense on both T1- and T2-weighted
images [12]. As a general rule, dysplastic nodules display the
same MRI characteristics as regenerative nodules [12]. Some
HCCs may demonstrate hyperintensity on T1-weighted
images and hypointensity on T2-weighted images, and,
therefore, can mimic regenerative and dysplastic nodules [12].
In such cases, arterial phase hypervascularity remains a dis-
tinguishing feature [12].
Two entities that should be noted include the occurrence
of HCC within a dysplastic nodule, and the hypovascular
HCC. The appearance of a dysplastic nodule with a central
focus of HCC was first described on T2-weighted images and
has been coined ‘‘a nodule within a nodule’’ (Figure 12, E-H)
[12], which appears as a hyperintense focus, which may also
demonstrate arterial phase enhancement, which occurs
within a low-signal-intensity nodule on T2-weighted images
[12]. Hypovascular HCCs have also been described as a rare
Figure 9. (A) Contrast-enhanced transaxial computed tomography (CT) on the arterial phase, demonstrating a hypervascular hepatocellular carcinoma (HCC)
(arrow) within liver segments 5/6, which invades into the right portal vein (arrowhead). (B) Coronal contrast-enhanced CT of the same patient with tumoural
invasion into the main portal vein (arrowheads). (C) Corresponding coronal fast imaging employing steady-state acquisition sequence with tumoural invasion of
the main portal vein (arrowhead).
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a nodule where there has been partial or complete loss of the
normal portal tract, without the associated increase in
arterialization to demonstrate arterial hypervascularity. These
lesions, therefore, will appear isointense or hypointense in
the arterial phase [12].
Typically, gadolinium chelates are used for MRI contrast
media. More recently, hepatocyte-targeted and reticuloen-
dothelial system targeted compounds, have become avail-
able, which allows for a wider range of tissue signal
manipulations [17,22].Figure 10. (A) A 60-year-old woman with hepatitis C and liver cirrhosis. Cont
demonstrating arterial enhancement and subtle washout to hypoattenuating to the
liver acceleration volume acquisition magnetic resonance imaging sequences with
of the liver mass (arrows) (D).Two hepatobiliary-targeted compounds are currently in
clinical usage: gadobenate dimeglumine (MultiHance;
Bracco Imaging, Montreal, QC) and gadoxetic acid (Gd-
EOB-DTPA; Primovist; Bayer Schering Pharma, Toronto,
ON) [17]. These agents are taken up by normal hepatocytes
and, therefore, allow both the visualization of vasculature as
well as hepatobiliary excretion [22]. Because hepatomas do
not have conventional hepatic microarchitecture and an
absence of both functional biliary ducts and Kupffer cell
lines, these alternative contrast media can be used for the
characterization of liver lesions. Well-differentiated andrast-enhanced transaxial computed tomography with a liver mass (arrows),
liver parenchyma on the portal venous phase (B). (C) Gadolinium-enhanced
corresponding arterial enhancement and washout on the portal venous phase
Figure 11. (A) Axial gradient echo T1 in phase sequence with an isointense mass located in segment 7, exhibiting signal intensity drop out on out-of-phase
sequence (B) consistent with intracytoplasmic fat (arrows). There is an additional hypointense mass located within the lateral aspect of segment 7 (arrowheads).
(C) Gadolinium-enhanced liver acceleration volume acquisition magnetic resonance image during the arterial phase, which demonstrate hypervascularity of the
mass (arrows) with corresponding washout on the portal venous phase (D). The additional lesion (arrowheads), showing progressive centripetal filling
throughout the phases (not all images shown) consistent with a cavernous hemangioma.
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volume of hepatocytes to take up these compounds, whereas
poorly differentiated lesions do not. Therefore, low-grade
HCCs enhance more intensely compared with high-grade
lesions [23].
Alternatively, reticuloendothelial systemetargeted
compounds, also known as superparamagnetic particles of
iron oxides, cause distortion of local magnetic fields and
result in signal loss on T2-weighted images [17]. Kupffer
cells within normal liver parenchyma take up more than 80%
these agents and, therefore, exhibit signal drop out [17]. In
contrast, poorly differentiated HCCs and metastasis do not
take up these agents and, therefore, appear relatively
hyperintense [17]. It should be noted that these agents are not
currently approved for use in Canada.
Discussion
The rising incidence of viral-associated hepatitis in
Canada has resulted in an increased incidence of HCC.
Recent estimates indicate that as of December 2007,
approximately 242,500 Canadians have been infected with
hepatitis C virus, which corresponds to a prevalence rate of
0.7% (R. Remis, unpublished data, 2009), and translating
into an estimated 2.2 per 100,000 in 2008. Countries of
highest endemic incidents are located in Africa, Latin
America, and Central and Southeast Asia, where, in these
regions, prevalence rates of 5%-10% are frequently reported
[24].Although the reported number and corresponding rates of
hepatitis B are decreasing, primarily due to immunization,
chronic hepatitis B remains a public health concern world-
wide. It is estimated that 2 billion people worldwide have
serologic evidence of past or present hepatitis B infection,
and 360 million are chronically infected and at risk for
hepatitis Berelated liver disease. Approximately one-third of
all cases of liver cirrhosis, and half of cases of HCC can be
attributed to chronic hepatitis B infection, with approxi-
mately 5%-6% of the population developing HCC [25]. The
sequelae of chronic hepatitis B infection results in a public
health concern that will extend decades beyond the initial
incidence. When combined, it is estimated that between
500,000 and 600,000 Canadians have been infected with
hepatitis B or C [26]. Current models predicted that 1565
new cases (1132 men, 433 women) and 802 deaths (654 men,
148 women) of HCC are expected to occur in Canada in
2010 [27]. With the increasing trend towards horizontal
transmission, particularly with hepatitis C virus, improved
population-based surveillance in the context of cost-effective
screening and diagnosis is paramount.
The AASLD criteria, revised as of July 2010 provides an
evidence-based consensus as to the most appropriate next
step in the management of a suspicious lesion in the at-risk
population. Compared with previous AASLD criteria, the
algorithm is significantly simplified and requires demon-
strable early arterial enhancement and early washout in
a single multiphase examination for the diagnosis of HCC.
Inferred from this algorithm, and perhaps most important, is
Figure 12. (A) Axial gradient echo T1 out-of-phase image, demonstrating a subtle isointense lesion (arrows) within segment 6, which, on the T2-weighted
sequence, is also isointense to the liver parenchyma (B). (C) Gadolinium-enhanced liver acceleration volume acquisition (LAVA) magnetic resonance imaging
(MRI) during the arterial phase, making the lesion (arrows) slightly more conspicuous but does not demonstrate enhancement on this phase, nor the portal venous
phase (D), and is consistent with a regenerative nodule. (E) T2-weighted MRI sequence on 1-year follow-up with the segment 6 lesion (arrow) now hyperintense
comparedwith the liver parenchyma. (F)Axial gradient echoT1 in phase image, demonstrating that the nodule is nowof increased signal intensity. (G)Gadolinium-
enhancedLAVAMRI sequence, demonstrating a focus of nodular arterial enhancement along itsmedial aspect (arrowheads) consistentwith the ‘‘nodule in nodule’’
appearance. This focus washes out and is hypointense to liver parenchyma on the portal venous phase (H), consistent with a focus of malignant transformation
within this nodule.
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a histopathologic diagnosis (biopsy).
In the high-risk population, as defined in the AALSD
criteria, the indications for continued enhanced follow-up iswarranted. As per the guidelines, the epidemiologic and
economic impact of appropriate surveillance is based upon
the availability of imaging (the guidelines are intentionally
nonspecific as to the initial modality of assessment, beyond
340 R. F. Rastegar et al. / Canadian Association of Radiologists Journal 63 (2012) 329e340US) and the potential risk to the patient, bearing in mind as
low as reasonably acceptable (ALARA) principles. Although
the current guidelines do not take into account the inherent
risks of cumulative radiation exposure, the societal impact of
failure to diagnose early presenting and potentially curable
disease currently outweighs the risk of high-frequency
follow-up imaging. As previously discussed, the risk of
complication, tumour seeding, tumour rupture, and associ-
ated cost of biopsy warrants a conservative approach to
biopsy of lesions that meet AASLD criteria and/or demon-
strate classic imaging characteristics within the at-risk pop-
ulation, as illustrated by this pictorial review.
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